Xu Y, Carpenter G
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
J Cell Biochem. 1999 Nov 1;75(2):264-71. doi: 10.1002/(sici)1097-4644(19991101)75:2<264::aid-jcb9>3.3.co;2-2.
Previously, we reported association of the adaptor protein Shc through its SH2 domain with the cytoplasmic domain of the adhesion molecule cadherin (Xu et al. [1997] J. Biol. Chem. 272:13463-13466). This association was dependent on tyrosine phosphorylation of cadherin and could be modulated by extracellular Ca(2+) and epidermal growth factor in intact cells. There are six tyrosine residues in the cytoplasmic domain of cadherin. To define the tyrosine residue(s) that mediate Shc recognition, site-directed mutagenesis was employed to alter Tyr851 and/or Tyr883 in cadherin, which both conform to a predicted Shc SH2 domain recognition sequence. Mutation of either Tyr851 or Tyr883, but mostly the latter, decreased Src phosphorylation of cadherin and the binding of Shc to cadherin, as determined by Sepharose bead binding and gel overlay assays. Of the two tyrosine residues, Tyr883 is the major Src phosphorylation and Shc binding site. However, the double mutant (Tyr851, 883 Phe) exhibited less Shc association than the single Tyr883 Phe mutant, suggesting a role for Tyr851 also. In addition, the binding of Shc to the cadherin cytoplasmic domain was competitively inhibited by tyrosine phosphorylated peptides containing either Tyr851 or Tyr883, but not by the corresponding non-phosphorylated peptides. Mutation of Tyr851 and/or Tyr883 did not alter the capacity of the cytoplasmic domain of cadherin to bind beta-catenin in vitro. However, Shc binding to cadherin did negatively influence beta-catenin binding to the same molecule.
此前,我们报道了衔接蛋白Shc通过其SH2结构域与黏附分子钙黏蛋白的胞质结构域相关联(Xu等人,[1997]《生物化学杂志》272:13463 - 13466)。这种关联依赖于钙黏蛋白的酪氨酸磷酸化,并且在完整细胞中可受到细胞外Ca(2+)和表皮生长因子的调节。钙黏蛋白的胞质结构域中有六个酪氨酸残基。为了确定介导Shc识别的酪氨酸残基,采用定点诱变来改变钙黏蛋白中的Tyr851和/或Tyr883,这两个残基均符合预测的Shc SH2结构域识别序列。通过琼脂糖珠结合和凝胶覆盖分析确定,Tyr851或Tyr883的突变,尤其是后者,会降低钙黏蛋白的Src磷酸化以及Shc与钙黏蛋白的结合。在这两个酪氨酸残基中,Tyr883是主要的Src磷酸化和Shc结合位点。然而,双突变体(Tyr851, 883 Phe)与Shc的关联比单突变体Tyr883 Phe更少,这表明Tyr851也发挥了作用。此外,Shc与钙黏蛋白胞质结构域的结合受到含有Tyr851或Tyr883的酪氨酸磷酸化肽段的竞争性抑制,但不受相应非磷酸化肽段的抑制。Tyr851和/或Tyr883的突变并未改变钙黏蛋白胞质结构域在体外结合β-连环蛋白的能力。然而,Shc与钙黏蛋白的结合确实对β-连环蛋白与同一分子的结合产生了负面影响。